In The News

    • APR 12 2016

    PharmaVoice Highlights Oncoceutics in Article on Innovative Funding for Biotechs

    Oncoceutics’ financing strategy, utilizing significant non-dilutive capital from grants and strategic partnerships with leading cancer institutes, was highlighted in an article published by PharmaVoice. The article, titled “Innovation Financing, Venture Capital and More” can be read in full here.

    • MAR 24 2016

    Oncoceutics Highlighted by German American Chamber of Commerce of Philadelphia

    The following article appeared in the March 2016 Member Newsletter of the German American Chamber of Commerce, Philadelphia Oncoceutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of highly differentiated treatments for difficult cancers. The company was founded in 2009 by GACC member Wolfgang Oster, Lee Schalop, and scientific founder Wafik

    • MAR 04 2016

    Dr. Joshua Allen Interviewed for the Innovator’s Corner by PharmaVoice

    Read the full article at PharmaVoice Dr. Joshua Allen, VP for Research and Development at Oncoceutics, talks about his company’s approach to target cancer. Targeted therapies are the focus of many cancer drug development programs. They are a cornerstone of precision medicine, which uses information about a person’s genes and proteins to prevent, diagnose, and

    • FEB 22 2016

    First-In-Class Drug ONC201 Shows Potential for Some Blood Cancers

    The University of Texas MD Anderson Cancer Center highlights the work of SAB member Dr. Michael Andreeff in highlighting the mechanism of ONC201 in liquid tumors. First-in-class drug ONC201shows potential for some blood cancers